anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because of the lack of reliable scientific data about this topic, the usual behaviours concerning the subsequent healing procedure after a punch skin biopsy remains still poorly defined and harmonized, currently based on the physicians personal experiences and some preconceived considerations. The few studies available in the literature are supporting the assumption that the use of a directed wound healing could be as effective as the widely-used procedure of performing a suture while it does not downgrade the quality of care. However, due to their methodological quality and applicability, they have not led to a substantial modification of the common behaviours. Moreover, the development of some new and the improvement of the former resources could have changed the situation. Therefore, this study aims to bring some recent pragmatic data to assist the implementation of recommendations regarding the attitude to adopt for the healing procedure after a skin punch-biopsy.

The protocol will consist in a monocentric, prospective, randomized and controlled, interventional study. It will be carried out with two parallel groups, in a non-inferiority setting. All the included participants will undergo a skin biopsy using a punch of 4 mm diameter. Then they will either get a suture by separated knots using a non-absorbable 4.0 wire and a dry dressing, either get only a dry dressing. All the subjects will receive a phone call at five days after the skin biopsy in order to collect the self-evaluation of the maximal experienced pain during the healing period. They will also have a single follow-up appointment one month after the inclusion and a photograph of the scar will be taken during this medical consultation. This picture will be evaluated by a blind independent investigator without the presence of the patient.
Individuals will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years). The CGM device will be used in blinded mode for both participants and providers (i.e., neither will be able to see glucose values).
PURPOSE: To obtain the titled stock solution, by adding sugar and a fermentation promotor to a natural food such as vegetable, fruit, etc., fermenting the blend with sending sterilizing air to give an enzyme stock solution, blending this stock solution with a raw material for Chinese orthodox medicine such as a medical food, etc. in a proper ratio, followed by fermentation.  
     CONSTITUTION: Sugar such as granulated sugar, etc. and a fermentation promotor (e.g., a yeast plant, etc.) is added to a natural food such as vegetable (e.g., cucumber, etc.), fruit (kumquat, etc.), seaweed (e.g., WAKAME seaweed, etc.), mushroom (e.g., Cortinellus shiitake, etc.), and the blend is fermented at 20°C for 70W80hr with stirring while sterilizing air is being introduced. The extracted solution of the raw material is collected from the resulted substance, fermented and aged to give an enzyme stock solution. This stock solution is blended with a raw material for Chinese orthodox medicine such as a medical food (e.g., Mallotus japonicus Muell. Arg., Epimedium macranthum Morr. et Dence. var. violaceum Franch, Polygonatum officinale All., etc.) in a weight ratio wherein the amount of the raw material for Chinese orthodox medicine is larger than that of the enzyme stock solution. Sterilizing air is introduced to the resulted blend, which is fermented, and an extracted solution is collected after three hours. The solution is aged for 3W4 months, to give an enzyme stock solution for Chinese orthodox medicine. 
     COPYRIGHT: (C)1982,JPO&Japio
The data collection form and scales will be applied to the patient before the patient is discharged from the clinic (pre-test). Routine training is provided by the wound and stoma care nurse before the patient is discharged from the clinic. The scale will be administered to the patient again via an online survey 4 weeks after discharge (posttest).
PURPOSE: The aim of this study is to identify likely pathogenic (LP) and pathogenic (P) genetic results for autism that can be returned to participants in SPARK (SPARKforAutism.org): a large recontactable cohort of people with autism in the United States. We also describe the process to return these clinically confirmed genetic findings.
METHODS: We present results from microarray genotyping and exome sequencing of 21,532 individuals with autism and 17,785 of their parents. We returned LP and P (American College of Medical Genetics criteria) copy-number variants, chromosomal aneuploidies, and variants in genes with strong evidence of association with autism and intellectual disability.
RESULTS: We identified 1903 returnable LP/P variants in 1861 individuals with autism (8.6%). 89.5% of these variants were not known to participants. The diagnostic genetic result was returned to 589 participants (53% of those contacted). Features associated with a higher probability of having a returnable result include cognitive and medically complex features, being female, being White (versus non-White) and being diagnosed more than 20 years ago. We also find results among autistics across the spectrum, as well as in transmitting parents with neuropsychiatric features but no autism diagnosis.
CONCLUSION: SPARK offers an opportunity to assess returnable results among autistic people who have not been ascertained clinically. SPARK also provides practical experience returning genetic results for a behavioral condition at a large scale.
The invention belongs to the technical field of biomedicine and provides a cyanea capillata thioredoxin. Currently, researches and reports related to jellyfish thioredoxin are not seen yet. The cyanea capillata thioredoxin provided by the invention has protein formed by an amino acid sequence shown in SEQ ID NO: 2. The invention further provides a coding gene of the cyanea capillata thioredoxin, wherein the coding gene has a nucleotide sequence shown in SEQ ID NO: 1. Meanwhile, the invention further provides application of the cyanea capillata thioredoxin and the coding gene of the cyanea capillata thioredoxin in preparation of anti-oxidation drugs, anti-radiation drugs, skin protectants, food preservatives, anti-aging drugs and the like. The cyanea capillata thioredoxin and the coding gene of the cyanea capillata thioredoxin have greater clinical application values.
PROBLEM TO BE SOLVED: To obtain the subject composition free from pain and paralytic feeling, having foaming ability and capable of providing stable and sufficient sterilizing effect even under weak alkali condition by using a polyoxyethylene alkyl ether as a foaming agent. SOLUTION: This composition is obtained by using a polyoxyethylene alkyl ether having >=20C alkyl group and >=20 ethylene oxide addition mole number, e.g. polyoxyethylene (30) alkyl ether (C20 ) as a foaming agent, preferably in an amount of 1.5-30wt.% based on total of the composition. The composition can be compounded with 0.005-0.5 cationic sterilizing agent (e.g. cecylpyridium). Hydrogencarbonate (e.g. sodium hydrogen carbonate) in an amount of 1-70wt.% can be compounded in order to promote release of dental plaque. Carbonate (e.g. sodium carbonate) can be compounded in an amount of 0.5-10wt.% by a similar purpose.
After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention "Korean version of telephone interview for cognitive status (TICS)". The test will be administered to spouse simultaneously by telephone.
The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?
Heterotopic hepatic tissue is a rare development anomaly, exhibiting diverse forms and locations. We present a case report of an asymptomatic woman in her 40s who had an 8 cm mass in the left hypochondrium detected on routine ultrasound, which was initially suspected to be a tumour. Further investigation revealed that the mass had a similar enhancement to the liver on gadoxetate disodium-enhanced MRI and presented a connection with the original liver via vascular pedicle, favouring the diagnosis of accessory liver lobe (ALL). Accurate differentiation of ALL from other abdominal masses poses a diagnostic challenge, potentially leading to misdiagnosis of malignant tumours and unnecessary interventions. Although usually small and asymptomatic, rarely they can present with acute complications, and cross-sectional techniques play an important role in enabling early diagnosis and management. Therefore, radiologists must raise awareness regarding ALL, their imagological findings, and diagnostic pathways, and understand potential associated complications.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent for neuropathies, containing a bonding inhibitor of P-selectin as an active ingredient and capable of effectively treating the neuropathies such as myelic damage, inflammatory central neuropathy or the neuropathy after ischemic reperfusion. SOLUTION: This therapeutic agent for neuropathies contains a bonding inhibitor of P-selection as an active ingredient. A substance capable of bonding to the P-selectin and thereby inhibiting the bonding to a ligand on a leukocyte is preferred as the bonding inhibitor. For example, an anti-P-selection antibody, a ligand of the P-selectin such as a glycoprotein on the leukocytic surface and its derivative, etc., are cited as the inhibitor of this kind. The objective medicine is preferably dissolved or suspended in an aqueous carrier such as water or a physiological saline and intravenously administered. The daily dose thereof is preferably 5-3,000mg expressed in terms of the active ingredient in a patient weighing 70kg.
Purpose: To compare post-operative refractive outcome with Sanders Retzlaff Kraff theoretical (SRK T) and Kane formulae for intraocular lens (IOL) power calculation in cataract patients Study Design: Prospective, interventional study Place and Duration of Study: Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Material and Methods: A total of a 70 eyes, 35 in each group will be included in our study. The patients will be randomly divided into two groups. In cases of bilateral cataract, one eye will be included in each group for better control. IOL power calculation in Group A will be done with the SRK-T formula and in group 2 with the Kane Formula. Autokeratometry and A-scan ultrasound will be done for biometry. Inclusion criteria will be uncomplicated cataract in both genders. Exclusion criteria will be ocular trauma, uveitis, previous intraocular surgery, or any retinopathy. All patients will undergo phacoemulsification with foldable lens implantation by two experienced surgeons. Post-operative refractive outcome will be evaluated at one month after surgery. The two groups will be compared.

Results: The results will be calculated by SPSS. Conclusion: A conclusion will be drawn on the basis of our results.
A method for making synthetic oligonucleotides which bind to target sequences in a duplex DNA forming colinear triplexes by binding to the major groove. The method includes scanning genomic duplex DNA and identifying nucleotide target sequences of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing synthetic oligonucleotides complementary to identified target sequences. The synthetic oligonucleotides have a G when the complementary location in the DNA duplex has a GC base pair and have a T when the complementary location in the DNA duplex has an AT base pair. The synthetic oligonucleotides are oriented 5' to 3' and bind parallel or 3' to 5' and bind anti-parallel to the about at least 65% purine strand. Also described are synthetic oligonucleotides made by the above methods. The oligonucleotides can be altered by modifying and/or changing the bases, adding linkers and modifying groups to the 5' and/or 3' termini, and changing the backbone. These synthetic oligonucleotides bind to duplex DNA to form triplexes. This process alters the functioning of the genes which are bound. This process can be used to inhibit cell growth, alter protein ratios, treat diseases including cancer and permanently alter the DNA.
Exercise therapies are effective methods in the treatment of complications after breast cancer surgery. The study aims to compare exercise practices with virtual reality-based exercise training during radiotherapy period after breast cancer surgery. Patients were randomly divided into 3 groups as virtual reality group, exercise group, and control group, considering the order of arrival at the clinic and the type of surgery (mastectomy and breast-conserving surgery). Patients in virtual reality group received virtual reality-based exercise training using Microsoft Xbox 360 Kinect (Redmond, WA). Patients in exercise group received an exercise program including range of motion, posture, stretching and breathing exercises. Both exercise groups participated in the exercise program for 30- 40 minutes, 3 days a week, as long as radiotherapy continued (5-6 weeks). Patients in the control group did not receive any exercise intervention as is done in the current practice. Assessment methods were applied at the beginning and at the end of the radiotherapy for all groups. Shoulder range of motion was measured using universal goniometer. Hand grip strength was measured using Jamar hand dynamometer. Shoulder proprioception was measured using Cybex (Lumex,NY,USA) isokinetic dynamometer. Upper extremity functional status, kinesiophobia, anxiety and depression level, fatigue and quality of life were evaluated with various questionnaires.
PURPOSE: A functional cosmetic composition for improving anti-wrinkle is provided to ensure collagen biosynthesis and to prevent toxicity and irritation to human body. CONSTITUTION: A functional cosmetic composition for improving anti-wrinkle contains 0.5-0.6 weight parts of tackifier, 0.2-0.4 weight parts of preservative, 0.04-0.1 weight parts of skin conditioning agent, 0.005-0.02 weight parts of sea water, and 0.01-0.02 weight parts of natural extract based on 100 weight parts of solvent. The tackifier is hydroxyethylcellulose. The preservative is propyl paraben, butyl paraben, methyl paraben, phenoxyethanol, or salicylic acid. The skin conditioning agent is adenosine, sodium hyluronate, acetyl hexapeptide-8 or human oligopeptide-1. The natural extract is opuntia ficus-indica extract, Fucus Vesiculosus Extract or mixture thereof.
HbA1c was predicted every month based on self-monitoring blood glucose for patients in HbA1c prediction model group. Study physicians adjusted patients' hypoglycemic therapy based on self-monitoring blood glucose records/glycated albumin and predicted HbA1c every month.
A charging system for use with an electric vehicle (EV) comprises a primary coil (32) which is excited to thereby generate an electromotive force in a secondary coil (22). A power battery device is provided in said electric vehicle (EV) and is charged by the electromotive force generated in said secondary coil (22). The primary coil (32) and secondary coil (22) include refrigerant passages (34) and a refrigerant is allowed to flow through the interior portion of said refrigerant passages to thereby cool said coils. A primary refrigerant passage is provided in the primary coil (32) for cooling the primary coil and a secondary refrigerant passage is provided in the secondary coil (22) for cooling the coil. In order to simplify the cooling system on the primary and secondary side passage joints (28, 39) for connecting the primary and secondary refrigerant passages to each other are respectively disposed opposed not only to the charging coupler (30) but also to a receive portion (13) formed in said electric vehicle (EV) for receiving the charging coupler (30), wherein the passage joints (28, 39) are connectable with each other when the charging coupler is mounted into the receive portion (13) to thereby bring said primary and secondary refrigerant passages into communication with each other. <IMAGE>
The starting dose for the subjects is 2 mg, administered once weekly for 4 consecutive weeks. If the subject shows good tolerability, the dose will then be escalated to 4 mg, also given once weekly, for another 8 weeks (with an escalation rate of increasing 2 mg every 4 weeks until reaching the target dose).
Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with "push and pull" motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan).
As with all drugs with beta-blocking activity, certain advice to patients being treated with labetalol HCl is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. While no incident of the abrupt withdrawal phenomenon (exacerbation of angina pectoris) has been reported with labetalol HCl, dosing with labetalol hydrochloride tablets should not be interrupted or discontinued without a physician’s advice. Patients being treated with labetalol hydrochloride tablets should consult a physician at any signs or symptoms of impending cardiac failure or hepatic dysfunction (see WARNINGS). Also, transient scalp tingling may occur, usually when treatment with labetalol hydrochloride tablets is initiated (see ADVERSE REACTIONS).
Particles and related methods are disclosed. The particles have an' impedance of at most 60 ohms at an applied power of two Watt, wherein the particles have a diameter of at most about 3,000 microns. The particles comprise a gelling precusor (e.g. alginate), and at least one polymer (e.g. polyvinyl alcohol) and optionally a ferromagnetic material. In some embodiments, the particles can be used to enhance tissue heating and/or ablation procedures or to transmit RF radiation.
FIELD: medicine, peptides, pharmacy. SUBSTANCE: invention relates to peptides-immunoregulators and their therapeutical usage. New peptides present peptide species consisting of 4-8 amino acids. Proposed peptides can be prepared as pharmaceutical compositions in any suitable form using carriers or vehicles. Medicinal agent containing new peptides is designated for treatment or prophylaxis of viral or bacterial infection or disease where immunostimulation is required. EFFECT: expanded assortment of agents of similar designation, valuable medicinal properties. 7 cl
PCT No. PCT/FR95/01489 Sec. 371 Date May 14, 1997 Sec. 102(e) Date May 14, 1997 PCT Filed Nov. 13, 1995 PCT Pub. No. WO96/14881 PCT Pub. Date May 23, 1996The invention relates to radio-pharmaceutical compositions that include an inclusion complex of a cyclodextrin and a radio-halogenated fatty acid. These complexes include a cyclodextrin such as  beta -cyclodextrin,  gamma -cyclodextrin and their derivatives, and a radio-halogenated fatty acid, in particular a fatty acid labelled with radioactive iodine such as 16-iodo 3-methyl hexadecanoic acid suitable for the examination of the myocardium by scintigraphy. The cyclodextrin allows the fatty acid to dissolve in aqueous solution without any addition of human blood albumin, while further improving the biodistribution of the fatty acid and its stability to heat.
In this study, the investigators undertake a 12-month cluster randomized trial in 96 households in the rural areas of Andhra Pradesh and Karnataka states of India. The investigators enrolled women (primary cook) and one child (age 8-15) in each of these 96 households. The investigators compare the effect of traditional wood burning stoves (the control condition) to that of improved wood burning stoves on the respiratory health of women and children, and also undertake community-based system dynamics modeling to delineate the feedback mechanisms involved in sustained use or abandonment of improved cookstoves. The study and research program are aligned with recent international attention to explore determinants impacting the sustained use of cleaner cooking systems in poor communities of the world. Thus, in achieving the aims of this R21, the investigators will then have: 1) necessary preliminary data; 2) pre-emptive strategies for most of these unanticipated but preventable challenges. The investigators will leverage these insights to proceed with a larger scale intervention: 1) to examine the effect of sustained use of cleaner cooking systems and respiratory health outcomes in women and children due to reduced HAP in rural India; 2) to explore barriers and enablers of implementation of cleaner cooking systems in multiple resource poor settings. Numerous studies have shown that sustained and exclusive use of cleaner cooking systems irrespective of their types have been a challenge. Lukewarm sustenance of cleaner cooking systems in poor households stems from a limited understanding on the grounds of social, technical, economic, and ecological intersections of energy security. The investigators intend to address this gap by using a trans-disciplinary approach to contribute to our understanding of factors that influence the implementation of cleaner cooking systems for rural poor in India.